Search research articles
Contact Us
Filters
Showing results (31-40 of 45) with videos related to
Page
of 5
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 2, 2022
Impact of acetaminophen on the efficacy of immunotherapy in cancer patients
A Bessede, A Marabelle, J P Guégan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 3, 2026
Cytokine Release Symptoms rather than Syndromes: A call for Granular Reporting of Cytokine Related Adverse Events in Clinical Trials
J-D Fumet, M Roulleaux Dugage, F-X Danlos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 20, 2021
Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance
Y Loriot, A Marabelle, J P Guégan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 18, 2021
Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?
A Laparra, M Kfoury, S Champiat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies
M Collins, J M Michot, F X Danlos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 9, 2022
Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study
M Maio, P A Ascierto, L Manzyuk, et al.
Cancer Immunology, Immunotherapy : CII
|
April 17, 2023
Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas
E Toulemonde, S Chevret, M Battistella, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 31, 2015
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
S Champiat, O Lambotte, E Barreau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 19, 2022
Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors
F Peyraud, J-P Guégan, D Bodet, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 15, 2016
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
J M Michot, C Bigenwald, S Champiat, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 45) with videos related to
Sort By:
Page
of 5
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 2, 2022
Impact of acetaminophen on the efficacy of immunotherapy in cancer patients
A Bessede, A Marabelle, J P Guégan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 3, 2026
Cytokine Release Symptoms rather than Syndromes: A call for Granular Reporting of Cytokine Related Adverse Events in Clinical Trials
J-D Fumet, M Roulleaux Dugage, F-X Danlos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 20, 2021
Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance
Y Loriot, A Marabelle, J P Guégan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 18, 2021
Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?
A Laparra, M Kfoury, S Champiat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies
M Collins, J M Michot, F X Danlos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 9, 2022
Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study
M Maio, P A Ascierto, L Manzyuk, et al.
Cancer Immunology, Immunotherapy : CII
|
April 17, 2023
Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas
E Toulemonde, S Chevret, M Battistella, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 31, 2015
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
S Champiat, O Lambotte, E Barreau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 19, 2022
Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors
F Peyraud, J-P Guégan, D Bodet, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 15, 2016
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
J M Michot, C Bigenwald, S Champiat, et al.
Page
of 5